Hematology

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

CAR T therapies are potentially revolutionizing the treatment of acute lymphoblastic leukemia (ALL).

After 4 years, the 1-time cost of valoctocogene roxaparvovec appeared to be more cost-effective than the annual cost of emicizumab prophylaxis for hemophilia A, according to a new Draft Evidence Report.

Receiving benefits from the SNAP program does not alleviate the issue, according to the analysis.

Management of marginal zone lymphoma was impacted by the COVID-19 pandemic because some treatment options can reduce B-cell-produced antibodies.

The agency’s decision data for the investigational factor VIII therapy from Sanofi and Soba is set for February 28, 2023.

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

A high proportion of myeloid cells may contribute to recurrence in those with long progression-free survival by promoting cancer growth and/or suppressing antitumor immunity.

The phase 2 AXIOMATIC trials assessing milvexian met its primary endpoints, with researchers anticipating a phase 3 trial to come within the year.

BleedCEASE is intended to stop bleeding from cuts and nosebleeds.

Tranexamic acid indicated for patients with hemophilia for short-term use to reduce or prevent hemorrhage and decrease the need for replacement therapy during and following tooth extraction.

Ibrutinib (Imbruvica) is the first therapy to gain FDA approval for younger patients who had no prior treatment options for chronic graft-versus-host disease.

Zynteglo is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell transfusions.

The regulatory submission includes data from the MOMENTUM phase 3 clinical trial that met all primary and key second efficacy end points.

The treatment regimen is first in more than 20 years to significantly improve outcomes in individuals with the fast-growing cancer, according to the company.

Kcentra is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy in adult patients with acute major bleeding.

For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.

Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.

Zoledronic acid (Zometa) is indicated for the treatment of hypercalcemia that may occur with cancer.

Both ibrutinib (Imbruvica) and venetoclax (Venclexta) carry an approved indication for use in chronic lymphocytic leukemia but do not often lead to complete remission, and therapy routinely continues indefinitely or until disease progression.

With costs for blood and blood products continuing to rise, appropriate blood use by hospitals is more important than ever.

A potential public health benefit of 13-valent pneumococcal conjugate vaccine is the reduction of acute chest syndrome among children with sickle-cell disease.

Humate-P is indicated for the treatment of adult patients with classical hemophilia (hemophilia A) and von Willebrand disease (VWD).

The company-sponsored phase 1/2 study evaluates a cryopreserved, readily available formulation for the treatment of follicular and diffuse large B cell lymphomas.

Topline results from the KarMMa-3 trial show that idecabtagene vicleucel significantly improves progression-free survival vs standard regimens.